Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Non-Current Deffered Revenue (2023 - 2025)

Ascentage Pharma Group International posted quarterly Non-Current Deffered Revenue of $29.6 million for Q4 2025, up 674.21% year-on-year from $3.8 million in Q4 2024, and up 674.21% on a QoQ basis from $3.8 million in Q4 2024.

Ascentage Pharma Group International (AAPG) has 3 years of Non-Current Deffered Revenue data on file, last reported at $29.6 million in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue rose 674.21% year-over-year to $29.6 million; the trailing twelve-month figure through Dec 2025 stood at $29.6 million (up 674.21% YoY), and the FY2025 full-year result was $929000.0, down 75.34% from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 stood at $29.6 million, up from $3.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $34.9 million in Q4 2023 and bottomed at $3.8 million in Q4 2024.
  • The 3-year median for Non-Current Deffered Revenue is $29.6 million (2025), against an average of $22.8 million.
  • The widest annual swing landed in 2024, when Non-Current Deffered Revenue tumbled 89.03%; it then jumped 674.21% in 2025.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $34.9 million in 2023, then plunged by 89.03% to $3.8 million in 2024, then surged by 674.21% to $29.6 million in 2025.
  • The last three Non-Current Deffered Revenue figures came in at $29.6 million (Q4 2025), $3.8 million (Q4 2024), and $34.9 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 225.10 Mn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn -
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 29.64 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 29.64 Mn
Dec 31, 2024 3.83 Mn
Dec 31, 2023 34.89 Mn